Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2.
AuthorsMiddleton, Mark R
Agarwala, Sanjiv S
AffiliationChristie Hospital, Manchester, United Kingdom.
MetadataShow full item record
AbstractRecent clinical trials in melanoma and leukemia have demonstrated potential for increased survival time and improved remission when histamine dihydrochloride is added to cytokine monotherapy. In the present study, the pharmacokinetics of subcutaneous histamine (1 mg) in 21 healthy subjects and 12 melanoma patients was determined via model-dependent methods. Drug-drug interactions with subcutaneous interleukin-2 (1.1 mg) were evaluated in a combined cohort of patients with melanoma (n = 8) or renal cell carcinoma (n = 4). Histamine dihydrochloride administered over 10 minutes in healthy subjects peaked at 18 minutes (Cmax 38 nmol/L), attained a distribution volume of 59 L, and was eliminated at 6%/min. The results were similar in a 20-minute infusion in melanoma patients. No gender effects were observed (p > 0.05). Interleukin-2 injected either 10 minutes prior to or 10 minutes following histamine dihydrochloride had no effect on histamine kinetics. Histamine dihydrochloride administered 10 minutes prior to injection of interleukin-2 also had no effect on interleukin-2 kinetics. Maximal concentration of interleukin-2 (2,442 pg/ml) occurred at 2.5 hours with an elimination half-life of 1.7 hours, area under the curve (AUC) of 15,746 pg x h/ml, and volume of distribution and plasma clearance of 194 L and 74 L/h, respectively. However, interleukin-2 Cmax (1,758 pg/ml) and AUC (12,448 pg x h/ml) were reduced when histamine dihydrochloride was infused 10 minutes following interleukin-2, likely due to the pharmacodynamic effects of histamine, including increased heart rate and reduced blood pressure. It is concluded that histamine dihydrochloride and interleukin-2 can be safely coadministered with minimal interaction.
CitationPharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2. 2002, 42 (7):774-81 J Clin Pharmacol
JournalJournal of Clinical Pharmacology
- Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.
- Authors: Perz JB, Ho AD
- Issue date: 2008 Apr
- Pharmacokinetic properties and safety profile of histamine dihydrochloride injection in Chinese healthy volunteers: a phase I, single-center, open-label, randomized study.
- Authors: Li J, Huang X, Wang Q, Jing S, Jiang H, Wei Z, Zang Y, Liu Y, Zhao L, Fang Y, Feng W
- Issue date: 2015 Oct 1
- Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.
- Authors: Lindnér P, Rizell M, Mattsson J, Hellstrand K, Naredi P
- Issue date: 2004 May-Jun
- Toxicology and toxicokinetics of acute and subchronic administration of histamine dihydrochloride in rats.
- Authors: Karavodin L, Jensen R, Sarno M, Gehlsen K
- Issue date: 2003 Feb
- Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.
- Authors: Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, Aulitzky WE
- Issue date: 1999 Dec